Compare Cytokinetics Inc (CYTK) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Las Vegas Sands Corp. — how do they compare? Cytokinetics Inc trades at $62.9 (market cap $8.62B), while Las Vegas Sands Corp. trades at $36.14 (market cap $23.38B). The key difference: Las Vegas Sands Corp. is far larger — about 2.7× Cytokinetics Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Las Vegas Sands Corp. for 72 Days on average.
| CYTK | LVS | |
|---|---|---|
Market Cap | $8.62B | $23.38B |
Volume | 2,594,626 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $69.49 |
52-Week Low | $54.76 | $35.81 |
Typical Hold Time | 19 Days | 72 Days |
Enterprise Value | $8.72B | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
LVS trades at $36.15, up 0.95% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong revenue growth to $13.02B in 2025 and a net income of $1.63B, with a P/E of 13.99 suggesting reasonable valuation. Recent news highlights Sands China's community initiatives and awards, while Q2 2026 earnings missed expectations.
The investment outlook is mixed: analyst consensus is bullish with a $59.78 price target, but high debt levels and a recent earnings miss pose risks. Upside potential exists if the company maintains revenue growth and executes its stock repurchase program, though sensitivity to Macao's tourism recovery and interest rates remains a key concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
